Reach Separations
Driven by increasing demand for its chromatography purification capabilities from the drug discovery, contract research and agrochemical sectors, Reach Separations is set to double laboratory space at its UK-based facility.
The expansion will see significant investment in analytical equipment and purification systems. “Adding a UPC2, QDa Mass spectrometry detector, HClass UPLC, rotary evaporators and two preparative SFCs will massively enhance our offering to the market," said director Phil Abbott. “For instance, the new equipment will allow us to use SFC with mass spectrometry, which is a very rare technique to see in the sector so is an exciting capability addition."
With a focus on providing purification with a rapid turnaround time to ensure the material is back in the hands of the chemist quickly, Reach Separations has built a reputation for being one of the most sophisticated chromatography purification providers in the contract services space. Director Phil Abbott said: “Our clients typically require purified materials as quickly as possible. Our expanded resource and capacity will allow us to work at increased speed to help reduce screen time and get compounds back to them even quicker, helping meet tight deadlines."
The company’s accelerated growth has also been bolstered by a thriving strategic alliance with Evotec, which has seen the company support the CRO in helping hit client deadlines on a consistent basis. After becoming a technology partner in 2014, Reach Separations has since provided ongoing purification, analytical and small molecule chromatography to aid Evotec’s pharmaceutical and biotech clients worldwide.
Supporting small molecule synthesis requirements, the company offers expertise in the fields of chiral, reverse phase and normal phase chromatography from mg scale to in excess of 500g.